Arcus Biosciences, Inc.
For the period ended Dec 31, 2025. Filed Feb 25, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 25, 2026
RCUS$18.95+3.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Table of Contents
| Page | ||
|---|---|---|
| Information Regarding Forward-Looking Statements | i | |
| Risk Factor Summary | iii | |
| PART I | ||
| Item 1. | Business | 1 |
| Item 1A. | Risk Factors | 25 |
| Item 1B. | Unresolved Staff Comments | 58 |
| Item 1C. | Cybersecurity | 59 |
| Item 2. | Properties | 60 |
| Item 3. | Legal Proceedings | 60 |
| Item 4. | Mine Safety Disclosures | 60 |
| PART II | ||
| Item 5. | Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities | 61 |
| Item 6. | Reserved | 62 |
| Item 7. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 63 |
| Item 7A. | Quantitative and Qualitative Disclosures About Market Risk | 73 |
| Item 8. | Financial Statements and Supplementary Data | 74 |
| Item 9. | Changes in and Disagreements With Accountants on Accounting and Financial Disclosure | 109 |
| Item 9A. | Controls and Procedures | 109 |
| Item 9B. | Other Information | 112 |
| Item 9C. | Disclosure Regarding Foreign Jurisdictions that Prevent Inspections | 112 |
| PART III | ||
| Item 10. | Directors, Executive Officers and Corporate Governance | 113 |
| Item 11. | Executive Compensation | 113 |
| Item 12. | Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters | 113 |
| Item 13. | Certain Relationships and Related Transactions, and Director Independence | 113 |
| Item 14. | Principal Accounting Fees and Services | 113 |
| PART IV | ||
| Item 15. | Exhibits and Financial Statement Schedules | 114 |
| SIGNATURES | 119 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.